World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
76
Citations
22818
World Ranking
1899
National Ranking
924

W. Ripley Ballou publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where W. Ripley Ballou sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 163 publications — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

W. Ripley Ballou D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where W. Ripley Ballou sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 76 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

W. Ripley Ballou is affiliated with the International AIDS Vaccine Initiative in the United States. Their research primarily focuses on topics related to malaria research and control, mosquito-borne diseases and control, HIV research and treatment, computational drug discovery methods, and vaccines and immunoinformatics approaches.

The main fields of study for this scientist include medicine and immunology and microbiology. Within these broader areas, Ballou's subfields of study focus on public health, environmental and occupational health, virology, computational theory and mathematics, and molecular biology.

Ballou has contributed to several recent papers, demonstrating involvement in both clinical and preclinical research related to malaria and immunology. Selected publications are:

  • A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults (2020) published in The Journal of Infectious Diseases
  • Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice (2021) published in Scientific Reports
  • The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection (2020) published in Frontiers in Immunology

Frequent co-authors of Ballou include Christian F. Ockenhouse, Jason A. Regules, Erik Jongert, Susan Cicatelli, and Elizabeth H. Duncan. Each of these collaborators has partnered on multiple works, indicating ongoing cooperative research efforts.

The most common publication venues associated with Ballou's work are The Journal of Infectious Diseases, Scientific Reports, and Frontiers in Immunology. This reflects a focus on infectious diseases, vaccine research, and immunology.

Best Publications

  • A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.

    J A Stoute;M Slaoui;D G Heppner;P Momin

  • First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

    Selidji Todagbe Agnandji;Bertrand Lell;Bertrand Lell;Solange Solmeheim Soulanoudjingar;Solange Solmeheim Soulanoudjingar

  • Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

    Pedro L. Alonso;Jahit Sacarlal;John J. Aponte;Amanda J Leach

  • Protection of Humans against Malaria by Immunization with Radiation-Attenuated Plasmodium falciparum Sporozoites

    Stephen L. Hoffman;Lucy M. L. Goh;Thomas C. Luke;Imogene Schneider

  • Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

    Kent E. Kester;James F. Cummings;Opokua Ofori-Anyinam;Christian F. Ockenhouse

  • A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.

    Selidji Todagbe Agnandji;Selidji Todagbe Agnandji;Bertrand Lell;Bertrand Lell;José Francisco Fernandes;José Francisco Fernandes

  • Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

    Kalifa A. Bojang;Paul J. M. Milligan;Margaret Pinder;Laurence Vigneron

  • SAFETY AND EFFICACY OF A RECOMBINANT DNA PLASMODIUM FALCIPARUM SPOROZOITE VACCINE

    W. Ripley Ballou;JamesA. Sherwood;JamesA. Sherwood;FranklinA. Neva;DanielM. Gordon

  • Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

    Pedro L Alonso;Jahit Sacarlal;John J Aponte;Amanda Leach

  • Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

    Philip Bejon;John Lusingu;Ally Olotu;Amanda Leach

  • A field trial to assess a blood-Stage malaria vaccine

    Mahamadou A. Thera;Ogobara K. Doumbo;Drissa Coulibaly;Matthew B. Laurens

  • Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

    D. M. Gordon;T. W. McGovern;U. Krzych;J. C. Cohen

  • Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

    Bernhards R. Ogutu;Odika J. Apollo;Denise McKinney;Willis Okoth

  • Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

    John J Aponte;John J Aponte;Pedro Aide;Montse Renom;Montse Renom;Inacio Mandomando

  • Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

    Kent E. Kester;Denise A. McKinney;Nadia Tornieporth;Christian F. Ockenhouse

  • A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

    Katie Ewer;Tommy Rampling;Navin Venkatraman;Georgina Bowyer

  • Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC-Pf7, a Pox-Vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium falciparum Malaria

    Christian F. Ockenhouse;Pei Fang Sun;David E. Lanar;Bruce T. Wellde

  • Long-Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine

    J A Stoute;K E Kester;U Krzych;B T Wellde

  • Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants

    Salim Abdulla;Rolf Oberholzer;Rolf Oberholzer;Omar Juma;Sulende Kubhoja

  • Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ

    Peifang Sun;Robert Schwenk;Katherine White;Jose A. Stoute

Frequent Co-Authors

Joe Cohen
Joe Cohen GlaxoSmithKline (United Kingdom)
D. Gray Heppner
D. Gray Heppner Crozet BioPharma
Kent E. Kester
Kent E. Kester Walter Reed Army Institute of Research
Amanda J. Leach
Amanda J. Leach Charles Darwin University
Christian F. Ockenhouse
Christian F. Ockenhouse Walter Reed Army Institute of Research
Pedro L. Alonso
Pedro L. Alonso University of Barcelona
Urszula Krzych
Urszula Krzych United States Army Research Laboratory
Quique Bassat
Quique Bassat University of Barcelona
David E. Lanar
David E. Lanar Walter Reed Army Institute of Research
Adrian V. S. Hill
Adrian V. S. Hill University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in advancing careers connected to immunology, exploring nursing and healthcare pathways can be highly beneficial. Many professionals pursue specialized online programs, such as the cheapest pmhnp certificate programs, which offer affordable routes to become Psychiatric-Mental Health Nurse Practitioners. These credentials enhance understanding of immune-related mental health disorders.

Salary expectations play a critical role in career planning. Prospective students and practitioners can research earning potential by location through resources like dnp salary by state, helping guide decisions about where to study or work after graduation.

Nurses looking to specialize further might consider bridge options that facilitate smooth transitions within the profession. A notable example is the fnp to acute care np bridge program, which enables Family Nurse Practitioners to gain acute care skills, often relevant in immunology-related cases.

To accelerate entry into these nursing specialties, many turn to accelerated fnp programs. These programs allow students to build advanced nursing skills rapidly, complementing their immunology knowledge and expanding career opportunities.

Best Scientists Citing W. Ripley Ballou

Trending Scientists

Recently Published Articles